膀胱癌初诊时膀胱镜预测分级与分期的前瞻性双盲临床研究
该前瞻性临床研究纳入因新发膀胱癌行经尿道膀胱肿瘤电切术的连续患者,由3名泌尿外科顾问医师仅根据初次电切时的膀胱镜下肿瘤形态预测分级和分期,并与盲法泌尿病理学家的评估比较。224例可分析患者中,低级别和高级别癌的阳性预测值分别为85.8%和71.3%,非肌层浸润性和肌层浸润性癌的准确预测率分别为93.4%和85.2%。作者认为泌尿外科医生似乎能可靠预测较低级别和肌层浸润性疾病。
要点
- 低级别和高级别膀胱癌的阳性预测值分别为85.8%和71.3%。
- 顾问医师将高级别癌预测为低级别的总体可能性为16/83(19.3%)。
- 肿瘤大于30 mm时该可能性降至7.3%(4/55),比值比=3.1(95%CI 1.0-9.7,P=.04)。
核心结论
- 对于新发膀胱癌患者,泌尿外科医生似乎能可靠地预测较低级别和肌层浸润性疾病,这证实了广泛持有的看法。
- 这允许根据组织学之前的风险分类,适当且有效地利用外科专业技术、可用技术和选择临床试验参与者。
研究设计与样本
- 前瞻性临床研究,纳入因新发膀胱癌接受经尿道膀胱肿瘤电切术的连续患者。
- 3名泌尿外科顾问医师仅根据初次经尿道膀胱肿瘤电切时的膀胱镜下肿瘤形态预测分级和分期,并记录在表格上。
- 预测结果与对临床预测不知情的泌尿病理学家的评估进行比较。
- 共248例患者,其中224例适合分析。
主要发现
- 低级别和高级别癌的阳性预测值分别为85.8%和71.3%。
- 顾问医师将高级别癌预测为低级别的总体可能性为16/83(19.3%)。
- 肿瘤大于30 mm时,该可能性降至7.3%(4/55)(比值比=3.1,95%置信区间=1.0-9.7,P=.04)。
- 非肌层浸润性和肌层浸润性癌的准确预测率分别为93.4%和85.2%。
- 161例预测为非肌层浸润性膀胱癌的肿瘤中,有6例(3.7%)组织学实际为肌层浸润性。
临床怎么用
- 作者认为,对于新发膀胱癌患者,泌尿外科医生似乎能可靠地预测较低级别和肌层浸润性疾病,这允许根据组织学之前的风险分类,适当且有效地利用外科专业技术、可用技术和选择临床试验参与者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess urologists' ability to predict the grade and stage of new bladder cancers from the cystoscopic features alone. PATIENTS AND METHODS: We conducted a prospective clinical study on consecutive patients who underwent transurethral resection of bladder tumor (TURBT) for new bladder cancers. Using only cystoscopic tumor morphology at the time of initial TURBT, 3 urology consultants predicted the grade and stage, recording these on a proforma along with tumor features. Predictions were compared with assessments by uropathologists, blinded to the clinical prediction. We analyzed the accuracy in (1) predicting the exact grade and stage of the cancer; (2) differentiating between low- and high-grade cancers; and (3) discerning between Ta, T1, and T2 cancers. RESULTS: Of 248 patients, 224 were suitable for analysis. The positive predictive values for low- and high-grade cancers were 85.8% and 71.3%, respectively. The overall likelihood of a consultant predicting high-grade cancers as being low grade was 16/83 (19.3%). When tumors were large (>30 mm), this likelihood dropped significantly to 7.3% (4/55) (odds ratio = 3.1, 95% confidence interval = 1.0-9.7, P = .04). Non-muscle-invasive and muscle-invasive cancers were predicted accurately in 93.4% and 85.2% patients, respectively. Six of 161 (3.7%) tumors predicted to be non-muscle-invasive bladder cancer were actually muscle invasive on histology. CONCLUSION: For clinical purposes, in newly presenting patients with bladder cancer, urologists appear to reliably predict lower grade and muscle-invasive disease, confirming widely held belief. This allows for appropriate and efficient use of surgical expertise, available technology, and selection of participants for clinical trials on the basis of prehistology risk categories.
引用
- Mariappan P, Lavin V, Phua CQ, et al. Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-a Prospective Double-Blind Clinical Study. Urology. 2017. PMID: 28818537. doi:10.1016/j.urology.2017.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。